Felony charges have been filed against a former Paxton pharmacist whose license was suspended by state regulators in 2023 ...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 4, 2025Idorsia Ltd (SIX: IDIA) today announced its ...

A scientific statement regarding pain and treatment considerations in patients with PAD has been published by the AHA.

In some cases, drug shortages are mitigated and patients don't experience any difficulty obtaining their drugs. For certain drugs, manufacturers are required by law to report anticipated and actual ...

We closed a great deal with Viatris for our Phase 3 assets, selatogrel and cenerimod, and we have advanced our early-stage pipeline of potentially first- or best-in-class discoveries. With commercial ...

No other drug class was significantly better than low ... Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta-analysis.

Obesity drugs have also started showing up in employer ... "We continue to see fundamental and strategic value for their potentially best-in-class portfolio of obesity and metabolic disease ...

Idorsia’s operating loss halved to CHF 308 million in 2024. QVIVIC sales nearly doubled, reaching CHF 61 million. The stock fell by 7.59% post-earnings. Strategic cost reductions included a ...